These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1044 related items for PubMed ID: 11443579

  • 1. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
    Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, Geller SA, Nichols WS, Fong TL.
    Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
    [Abstract] [Full Text] [Related]

  • 2. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
    Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, Chang MH, Lee PH.
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
    [Abstract] [Full Text] [Related]

  • 3. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
    Castells L, Vargas V, Rodríguez F, Allende H, Buti M, Sánchez-Avila JF, Jardí R, Margarit C, Pumarola T, Esteban R, Guardia J.
    Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
    [Abstract] [Full Text] [Related]

  • 4. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
    Prieto M, Gómez MD, Berenguer M, Córdoba J, Rayón JM, Pastor M, García-Herola A, Nicolás D, Carrasco D, Orbis JF, Mir J, Berenguer J.
    Liver Transpl; 2001 Jan; 7(1):51-8. PubMed ID: 11150423
    [Abstract] [Full Text] [Related]

  • 5. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
    Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R.
    Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
    [Abstract] [Full Text] [Related]

  • 6. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, Boccadoro M, Rizzetto M, Bruno B, Marzano A.
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [Abstract] [Full Text] [Related]

  • 7. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation.
    Holt D, Thomas R, Van Thiel D, Brems JJ.
    Arch Surg; 2002 May; 137(5):572-5; discussion 575-6. PubMed ID: 11982471
    [Abstract] [Full Text] [Related]

  • 8. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW.
    Clin Transplant; 2006 May; 20(3):369-73. PubMed ID: 16824156
    [Abstract] [Full Text] [Related]

  • 9. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool.
    Donataccio D, Roggen F, De Reyck C, Verbaandert C, Bodeus M, Lerut J.
    Transpl Int; 2006 Jan; 19(1):38-43. PubMed ID: 16359375
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation.
    Ben-Ari Z, Zemel R, Kazetsker A, Fraser G, Tur-Kaspa R.
    Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648
    [Abstract] [Full Text] [Related]

  • 11. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure.
    Abdelmalek MF, Pasha TM, Zein NN, Persing DH, Wiesner RH, Douglas DD.
    Liver Transpl; 2003 Dec; 9(12):1253-7. PubMed ID: 14625824
    [Abstract] [Full Text] [Related]

  • 12. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants.
    Caccamo L, Romeo R, Rossi G, Maggioni M, Radice F, Lunghi G, Colombo M, Fassati LR.
    Transpl Int; 2005 Feb; 18(2):186-92. PubMed ID: 15691271
    [Abstract] [Full Text] [Related]

  • 13. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation.
    Shitrit AB, Kramer MR, Bakal I, Morali G, Ben Ari Z, Shitrit D.
    Ann Thorac Surg; 2006 May; 81(5):1851-2. PubMed ID: 16631684
    [Abstract] [Full Text] [Related]

  • 14. [Lamivudine as prophylaxis against hepatitis B virus reinfection following orthotopic liver transplantation].
    Zheng S, Wu J, Wang W, Huang D, Liang T, Lu A.
    Zhonghua Yi Xue Za Zhi; 2002 Apr 10; 82(7):445-8. PubMed ID: 12133511
    [Abstract] [Full Text] [Related]

  • 15. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
    Yang Y, Yang Y, Zhang J, Yi HM, Lu MQ, Cai CJ, Li X, Jiang N, Xu C, Li H, Wang GS, Yi SH, Zhang JF, Jiang H, Yang Q, Chen GH.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct 10; 28(10):1810-2. PubMed ID: 18971179
    [Abstract] [Full Text] [Related]

  • 16. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors.
    Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ.
    Transplantation; 1999 Oct 15; 68(7):1058-61. PubMed ID: 10532552
    [Abstract] [Full Text] [Related]

  • 17. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis.
    Cheung CK, Lo CM, Man K, Lau GK.
    Liver Transpl; 2010 Nov 15; 16(11):1314-23. PubMed ID: 21031547
    [Abstract] [Full Text] [Related]

  • 18. Anti-hepatits B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice.
    Bhatti FA, Ullah Z, Salamat N, Ayub M, Ghani E.
    Transfusion; 2007 Jan 15; 47(1):74-9. PubMed ID: 17207233
    [Abstract] [Full Text] [Related]

  • 19. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
    Vizzini G, Gruttadauria S, Volpes R, D'Antoni A, Pietrosi G, Filì D, Petridis I, Pagano D, Tuzzolino F, Santonocito MM, Gridelli B.
    Clin Transplant; 2011 Jan 15; 25(1):E77-81. PubMed ID: 21039887
    [Abstract] [Full Text] [Related]

  • 20. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.
    Lu SC, Yan LN, Li B, Wen TF, Zhao JC, Cheng NS, Liu C, Liu J, Wang XB, Li XD, Qin S, Zhao LS, Lei BJ, Zhang XH.
    Hepatobiliary Pancreat Dis Int; 2004 Feb 15; 3(1):26-32. PubMed ID: 14969833
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.